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Background:  The CHADS2 score is widely used and well validated for stroke risk stratification in patients with atrial fibrillation (AF). However, the 
component comorbidities of the CHADS2 score are also associated with stroke independent of AF, particularly in patients with coronary heart disease 
(CHD). Therefore, we evaluated the prognostic performance of CHADS2 for ischemic stroke in CHD patients without AF.
Methods:  The Heart and Soul study is a prospective cohort study of patients with stable CHD enrolled between 2000 and 2002. Of 1024 subjects, 
we identified 916 non-anticoagulated outpatients with no baseline evidence of AF by electrocardiogram. We calculated CHADS2 score based on 
history of heart failure, hypertension, age ≥ 75, diabetes, and prior stroke or transient ischemic attack (TIA). The primary outcome was time to 
ischemic stroke or TIA determined by blinded review of medical records over a mean follow-up of 6.4 ± 2.3 years.
Results:  The mean baseline CHADS2 score was 1.7 ± 1.2. Stroke/TIA occurred in 40 of 916 patients (4.4%), and risk increased by CHADS2 score 
(0: 1.4%, 1: 2.7%, 2: 5.7%, 3: 5.5%, 4: 6.4%, 5-6: 17.4%, p =0.006 ). Compared to patients with low CHADS2 score (0-1), those with intermediate 
(2-3) and high (4-6) CHADS2 scores had significantly increased rates of stroke/TIA (CHADS2 score 2-3: HR 2.7, 95% CI 1.3-5.7, p=0.01; CHADS2 
score 4-6: HR 4.6, 95% CI 1.8-11.8, p=0.001). Findings were similar after adjustment for age, tobacco, antiplatelet therapy, statins, and angiotensin 
blockers (CHADS2 score 2-3: HR 2.4, 95% CI 1.1-5.3, p=0.03, CHADS2 score 4-6: HR 4.0, 95% CI 1.5-10.6, p=0.006). Model discrimination (c 
statistic = 0.65) was comparable to CHADS2 model fit in published AF-only cohorts.
Conclusions:  CHADS2 predicts ischemic stroke and TIA in patients with stable CHD who have no known baseline AF. Model discrimination in 
this non-AF cohort is similar to that observed in AF-only cohorts. These findings may have public health implications and should inform efforts to 
determine benefit of stroke prevention therapies or screening for silent AF in this population.
